Beihai Biotechnology

Beihai Biotechnology is a Beijing-based biopharmaceutical company specializing in the development of innovative gene therapies and oncolytic viruses for oncology. The company achieved global recognition for the development of Oncorine (H101), which in 2005 became the first oncolytic virus therapy approved by a regulatory agency for the treatment of cancer. Beihai Biotechnology focuses on leveraging viral vector technologies to create targeted treatments that selectively replicate in and destroy cancer cells while sparing healthy tissue. Its pipeline includes several recombinant adenovirus candidates targeting various solid tumors, including head and neck and liver cancers. The company maintains a strong focus on the Chinese market while integrating research, development, and clinical strategy to address unmet needs in oncology. Its pioneering work has established it as a foundational player in the field of viral-based cancer therapeutics.